Emerging Issues in Oncology-Updates from ASH
Originally presented February 16, 2017
- Evaluate key research findings presented at the 2016 ASH Annual Meeting pertaining to multiple myeloma (MM) and lymphoma
- Explain key research findings presented at the 2016 ASH Annual Meeting pertaining to acute leukemia
- Summarize key research findings presented at the 2016 ASH Annual Meeting pertaining to hematopoietic cell transplantation (HCT)
Statement of Need/Activity Purpose:
This session will summarize key research findings presented at the 2016 ASH Annual Meeting pertaining to multiple myeloma, lymphoma, leukemia, and hematopoietic cell transplantation.
Alex Ganetsky, PharmD BCOP
Alex Ganetsky is a board-certified hematology/oncology clinical pharmacy specialist at the Hospital of the University of Pennsylvania. He specializes in malignant hematology and hematopoietic cell transplantation. He earned his PharmD degree from Temple University in 2008 and subsequently completed a pharmacy practice residency at the University of North Carolina and a hematology/oncology specialty residency at Memorial Sloan Kettering Cancer Center. He has presented his work at national and international conferences and has published numerous articles in leading peer-reviewed journals. His primary research focus is related to identifying novel methods to mitigate complications of hematopoietic cell transplantation.
Disclosure: Received consulting fees from Jazz and Juno. Received fees for Non-CPE services from Amgen.
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-17-042-L01-P.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved. Tests must be completed by August 16, 2017.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.
This webinar is part of the BCOP program bundle.